Future studies will utilize pathway-specific inhibitors, NFκB translocation assays, cytokine profiling, and CRC-relevant murine models (such as AOM/DSS-induced CRC) to validate the mechanistic dependencies and therapeutic relevance of the isolated metabolites. The gene discussed is NFKB1; the disease is colorectal carcinoma.